The world is currently experiencing a huge challenge which has affected all the industries and markets. Few markets have experienced a high growth in their demand while others have faced a downfall. The extent of growth or drop in the market statistics of different industries by COVID 19 plays an important role in how the future of businesses will shape up in the near future. We at Value Market Research provide you with an impact analysis of COVID 19 on this market with its latest update in the purchased version of the report.
Global Retinal Biologics Market Report By Drug Class (VEGF-A Antagonist,TNF-a Inhibitor), By Disease Indication,Macular Degeneration,Diabetic Retinopathy,Uveitis,Others) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2021-2028
ID:VMR11213856
April 2021
Report Formats: Electronic (PDF), MS EXCEL
The global demand for Retinal Biologics Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period of 2022-2028.
Retinal biologics are macromolecules like genetically engineered protein, peptides, and aptamers used as therapeutic agents to treat various ocular diseases. Ocular inflammation can occur in patients with inflammatory bowel disease (IBD), ankylosing spondylitis (AS), psoriasis, Bechet's disease (BD), juvenile idiopathic arthritis (JIA), and rheumatoid arthritis (RA). Biologics are delivered to the tissues at the back of the eyes for patients with recalcitrant diseases who are intolerant to immunosuppressive therapy or conventional immunomodulatory therapy. Retinal biologics has been extensively used in children with uveitis and treats age-related macular degeneration and other retinal vascular diseases.
Market Dynamics
The retinal biologics market is witnessing significant momentum in recent years due to the escalation of ophthalmic disorders worldwide. Growing instances of retinal conditions like macular degeneration related to age, infectious retinitis, macular edema, diabetic retinopathy, macular hole, retinoblastoma, retinal degeneration, uveitis, and retinoschisis leading to a permanent loss of vision will be the primary stimulant for the growth of this market. Consistent efforts in developing innovative treatment options, increased investments in the ophthalmology sector to raise awareness and diagnosis of different disorders related to the eye will be a market booster. The high treatment cost and limited long-term safety will hamper market growth since retinal biologics is not considered first-line therapy in most patients.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each segment in the global market of retinal biologics.
Market Segmentation
This section of the retinal biologics market report provides detailed data on the segments by analyzing them geographically, thereby assisting the strategist in identifying the target demographics for the respective product or service.
By Drug Class
By Disease Indication
Regional Analysis
This section covers regional segmentation which accentuates on current and future demand for Retinal Biologics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Retinal Biologics Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the retinal biologics market include F. Hoffmann-La Roche Ltd,Regeneron Pharmaceuticals Inc.,AbbVie Inc.,MeiraGTx Limited,Oxurion NV,Others. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
Retinal biologics are macromolecules like genetically engineered protein, peptides, and aptamers used as therapeutic agents to treat various ocular diseases. Ocular inflammation can occur in patients with inflammatory bowel disease (IBD), ankylosing spondylitis (AS), psoriasis, Bechet's disease (BD), juvenile idiopathic arthritis (JIA), and rheumatoid arthritis (RA). Biologics are delivered to the tissues at the back of the eyes for patients with recalcitrant diseases who are intolerant to immunosuppressive therapy or conventional immunomodulatory therapy. Retinal biologics has been extensively used in children with uveitis and treats age-related macular degeneration and other retinal vascular diseases.
Market Dynamics
The retinal biologics market is witnessing significant momentum in recent years due to the escalation of ophthalmic disorders worldwide. Growing instances of retinal conditions like macular degeneration related to age, infectious retinitis, macular edema, diabetic retinopathy, macular hole, retinoblastoma, retinal degeneration, uveitis, and retinoschisis leading to a permanent loss of vision will be the primary stimulant for the growth of this market. Consistent efforts in developing innovative treatment options, increased investments in the ophthalmology sector to raise awareness and diagnosis of different disorders related to the eye will be a market booster. The high treatment cost and limited long-term safety will hamper market growth since retinal biologics is not considered first-line therapy in most patients.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each segment in the global market of retinal biologics.
Market Segmentation
This section of the retinal biologics market report provides detailed data on the segments by analyzing them geographically, thereby assisting the strategist in identifying the target demographics for the respective product or service.
By Drug Class
- VEGF-A Antagonist
- TNF-a Inhibitor
By Disease Indication
- Macular Degeneration
- Diabetic Retinopathy
- Uveitis
- Others
Regional Analysis
This section covers regional segmentation which accentuates on current and future demand for Retinal Biologics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Retinal Biologics Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the retinal biologics market include F. Hoffmann-La Roche Ltd,Regeneron Pharmaceuticals Inc.,AbbVie Inc.,MeiraGTx Limited,Oxurion NV,Others. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . RETINAL BIOLOGICS – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 By Drug Class
3.7.2 By Disease Indication
3.7.3 By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
5.1. Impact Analysis of Covid-19 Outbreak
5.1.1. Direct Impact on Production
5.1.2. Supply Chain and Market Disruption
5.1.3. Financial Impact on Firms and Financial Markets
5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
5.3. Market: Pre V/S Post COVID-19
5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
5.5. COVID-19: Micro and Macro Factor Analysis
6 . GLOBAL RETINAL BIOLOGICS MARKET ANALYSIS BY DRUG CLASS
6.1 Overview by Drug Class
6.2 Historical and Forecast Data
6.3 Analysis by Drug Class
6.4 VEGF-A Antagonist Market by Regions
6.6 TNF-a Inhibitor Market by Regions
7 . GLOBAL RETINAL BIOLOGICS MARKET ANALYSIS BY DISEASE INDICATION
7.1 Overview by Disease Indication
7.2 Historical and Forecast Data
7.3 Analysis by Disease Indication
7.4 Macular Degeneration Market by Regions
7.5 Diabetic Retinopathy Market by Regions
7.6 Uveitis Market by Regions
7.7 Others Market by Regions
8 . GLOBAL RETINAL BIOLOGICS MARKET ANALYSIS BY GEOGRAPHY
8.1. Regional Outlook
8.2. Introduction
8.3. North America
8.3.1. Overview, Historic and Forecast Data
8.3.2. North America By Segment
8.3.3. North America By Country
8.3.4. United State
8.3.5. Canada
8.3.6. Mexico
8.4. Europe
8.4.1. Overview, Historic and Forecast Data
8.4.2. Europe by Segment
8.4.3. Europe by Country
8.4.4. United Kingdom
8.4.5. France
8.4.6. Germany
8.4.7. Italy
8.4.8. Russia
8.4.9. Rest Of Europe
8.5. Asia Pacific
8.5.1. Overview, Historic and Forecast Data
8.5.2. Asia Pacific by Segment
8.5.3. Asia Pacific by Country
8.5.4. China
8.5.5. India
8.5.6. Japan
8.5.7. South Korea
8.5.8. Australia
8.5.9. Rest Of Asia Pacific
8.6. Latin America
8.6.1. Overview, Historic and Forecast Data
8.6.2. Latin America by Segment
8.6.3. Latin America by Country
8.6.4. Brazil
8.6.5. Argentina
8.6.6. Peru
8.6.7. Chile
8.6.8. Rest of Latin America
8.7. Middle East & Africa
8.7.1. Overview, Historic and Forecast Data
8.7.2. Middle East & Africa by Segment
8.7.3. Middle East & Africa by Country
8.7.4. Saudi Arabia
8.7.5. UAE
8.7.6. Israel
8.7.7. South Africa
8.7.8. Rest Of Middle East And Africa
9 . COMPETITIVE LANDSCAPE OF THE RETINAL BIOLOGICS COMPANIES
9.1. Retinal Biologics Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments
10 . COMPANY PROFILES OF RETINAL BIOLOGICS INDUSTRY
10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. F. Hoffmann-La Roche Ltd.
10.3.1. Company Overview
10.3.2. Financials
10.3.3. Products
10.3.4. Recent Developments
10.4. Regeneron Pharmaceuticals Inc.
10.4.1. Company Overview
10.4.2. Financials
10.4.3. Products
10.4.4. Recent Developments
10.5. AbbVie Inc.
10.5.1. Company Overview
10.5.2. Financials
10.5.3. Products
10.5.4. Recent Developments
10.6. MeiraGTx Limited
10.6.1. Company Overview
10.6.2. Financials
10.6.3. Products
10.6.4. Recent Developments
10.7. Oxurion NV
10.7.1. Company Overview
10.7.2. Financials
10.7.3. Products
10.7.4. Recent Developments
10.8. Others
10.8.1. Company Overview
10.8.2. Financials
10.8.3. Products
10.8.4. Recent Developments
*Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
LIST OF TABLES
- Market Snapshot
- Drivers : Impact Analysis
- Restraints : Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- List of Potential Buyers
- COVID-19 Impact Analysis by Production, Import, Export and Demand
- Pre V/S Post COVID-19
- Estimated Impact Of The Coronavirus (Covid-19) Epidemic
- COVID-19: Micro and Macro Factor Analysis
- Analysis by Drug Class (USD MN)
- VEGF-A Antagonist Market by Geography (USD MN)
- TNF-a Inhibitor Market by Geography (USD MN)
- Analysis Market by Disease Indication (USD MN)
- Macular Degeneration Market by Geography (USD MN)
- Diabetic Retinopathy Market by Geography (USD MN)
- Uveitis Market by Geography (USD MN)
- Others Market by Geography (USD MN)
- Global Retinal Biologics Market by Geography (USD MN)
- North America Market Analysis (USD MN)
- United State Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate by Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisiton
LIST OF FIGURES
- Research Scope of Retinal Biologics Report
- Market Research Process
- Market Research Methodology
- Global Retinal Biologics Market Size, by Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis by Drug Class
- Market Attractiveness Analysis by Disease Indication
- Market Attractiveness Analysis by Region
- Value Chain Analysis
- Global Market Analysis by Drug Class (USD MN)
- VEGF-A Antagonist Market by Geography (USD MN)
- TNF-a Inhibitor Market by Geography (USD MN)
- Global Market Analysis by Disease Indication (USD MN)
- Macular Degeneration Market by Geography (USD MN)
- Diabetic Retinopathy Market by Geography (USD MN)
- Uveitis Market by Geography (USD MN)
- Others Market by Geography (USD MN)
- Global Market by Revenue
- North America Market by Revenue
- Europe Market by Revenue
- Asia Pacific Market by Revenue
- Latin America Market by Revenue
- Middle East & Africa Market by Revenue
- Recent Development in Industry
- Company Market Share Analysis
* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
Related Categories
Biotechnology
Buy Chapters or Sections
Avail customized purchase options to meet your exact research needs:
- Buy sections of this report
- Buy country level reports
- Request for historical data
- Request discounts available for Start-Ups & Universities
Objectives of Study
- Define and measure the global market
- Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
- Analyze and identify major market trends along with the factors driving or inhibiting the market growth
- Study the company profiles of the major market players with their market share
- Analyze competitive developments